SELLAS Life Sciences Group, Inc. (SLS )

Currency in USD Disclaimer
$12.39 +$1.86 (17.66%)
Closed 06/26/2026
$10.32
$12.43
$1.39
$9.51

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol SLS
  • Company SELLAS Life Sciences Group, Inc.
  • Price $12.39
  • Changes Percentage 17.66
  • Change 1.86
  • Day Low $10.32
  • Day High $12.43
  • Year High $9.51
  • Year Low $1.39
  • Market Cap $1,166,599,980
  • Price Avg 50 EMA (D) $5.73
  • Price Avg 200 EMA (D) $3.53
  • Exchange NASDAQ
  • Volume 7,442,962
  • Average Volume 7,856,906
  • Open $10.39
  • Previous Close $10.53
  • EPS -0.23
  • PE -35.61
  • Earnings Announcement 2026-08-11 20:00:00
  • Shares Outstanding $142,442,000

Company brief: SELLAS LIFE SCIENCES GROUP, INC. (SLS )

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

SLS Corporation News

Income Statement